Medically Reviewed By
Dr. Aditya Singh, MBBS, MD (Pharmacology)
Reg No: MCI-654321 • Verified Medical Reviewer
Imjudo
(tremelimumab)
Uses, side effects, dosage information & price range
About this medicine
Imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.
Common Substitutes & Alternatives
These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.
Key Information
Salt / Composition
tremelimumab
Category
Antineoplastic agents
Manufacturer
AstraZeneca AB
Medical Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice. Always consult your doctor or pharmacist before taking any medication. Prices are indicative and may vary. Do not start, stop, or change the dosage of any medicine without your doctor's approval.
Disclaimer:Content on this page is for informational purposes only. Do not consume prescription medication without a registered practitioner's direct oversight.